Sotorasib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-SOTORASIB |
|---|---|
| Type | Drug |
| Aliases | LumakrasСотерасіб |
| Status | pending_clinical_signoff |
| Diseases | DIS-CRC DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | KRAS G12C-selective covalent inhibitor |
|---|---|
| Mechanism | First-in-class covalent inhibitor of KRAS G12C — locks the protein in its inactive GDP-bound state. CodeBreaK 100: ORR ~37% in pretreated KRAS G12C+ NSCLC. |
| Typical dosing | 960 mg PO once daily. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
CodeBreaK 200 vs docetaxel in 2L: PFS benefit, OS not significant. Approved 2L+ for KRAS G12C-mutant NSCLC.
Used By
Regimens
REG-SOTORASIB-CETUXIMAB-CRC- Sotorasib + Cetuximab (CodeBreaK 300, KRAS G12C+ mCRC)REG-SOTORASIB-KRAS- Sotorasib monotherapy (KRAS G12C+ NSCLC, 2L+)